Synthetic Biologics Inc.

AMEX: SYNHealthcare / Biotechnology / USA
0.5300-0.0100-1.85%Vol 41 0801Y Perf -93.05%
Jun 24th, 2019 15:59
BID0.0000 ASK0.0000
Open0.5500 Previous Close0.5500
Pre-Market- After-Trading-
 - -%  - -%
Target Price
6.00 
Analyst Rating
— 0.00
Potencial %
1 032.08 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-100/-100/-100 
Income Ranking
 —    -
Market Cap (mil)9 
Earnings Rating
Buy
Price Range Ratio 52wk %
0.46 
Earnings Date
14th Aug 2019

Today's Price Range

0.53000.5500

52wk Range

0.49009.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Month
-3.64%
3 Months
-22.06%
6 Months
1.92%
1 Year
-93.05%
3 Years
-99.11%
5 Years
-99.11%

Name / TickerPriceChg.Chg.%
SYN0.5300-0.0100-1.85
AAPL198.58-0.2000-0.10
GOOG1 115.52-6.3600-0.57
MSFT137.780.81000.59
XOM76.95-0.7400-0.95
WFC46.27-0.6200-1.32
JNJ143.060.97000.68
FB192.601.46000.76
GE10.28-0.2000-1.91
JPM108.66-0.7800-0.71
Earnings HistoryEstimateReportedSurprise %
Q01 2019--0.25-
Q04 2018-0.17-1.33-682.35
Q03 2018-1.32-0.9329.55
Q02 2018-1.40-1.0525.00
Q01 2018-1.75-0.7060.00
Q04 2017-1.750.70140.00
Q03 2017-1.75-4.90-180.00
Q02 2017-2.45-1.0557.14
Earnings Per EndEstimateRevision %Trend
3/2019 QR-0.64-300.00Negative
6/2019 QR-0.61-281.25Negative
12/2019 FY-2.48-270.15Negative
12/2020 FY-2.54--
Next Report Date14th Aug 2019
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume41 080
Shares Outstanding (in ths.)16 484
Trades Count83
Dollar Volume21 766
Avg. Volume238 388
Avg. Weekly Volume66 842
Avg. Monthly Volume103 571
Avg. Quarterly Volume133 320
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Rating--Strong Buy
1.00

Synthetic Biologics Inc.

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.

CEO: Steven A. Shallcross

Teplephone: +1 301 417-4364

Address: 9605 Medical Center Drive, Rockville 20850, MD, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

73%27%

Bearish Bullish

30%70%

Bearish Bullish

64%36%

News